[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,62,95,120,144,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100525332","the-swedish-biofinder---primary-care-study-100525332",false,"NCT06120361","The Swedish BioFINDER - Primary Care Study","ADetect","Inclusion Criteria:\n\n1. The patient seeks medical help because of cognitive symptoms experienced by the patient and\u002For informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment.\n2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints.\n3. Age ≥40 years\n4. Subjective cognitive decline, mild cognitive impairment or mild dementia\n\nExclusion Criteria:\n\n1. Already diagnosed dementia\n2. Significant unstable systemic illness or organ failure that makes it difficult to participate.\n3. Current significant alcohol or substance misuse.\n4. Refusing investigation at the Memory clinic\n5. Cognitive impairment with acute onset due to stroke\n6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.","ALL","40 Years",{"count":19,"type":20},1200,"ESTIMATED","OBSERVATIONAL","The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to:\n\n1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care.\n2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care.\n3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care.\n4. Determine whether blood AD biomarkers improve patient management in primary care.",[24,25,26,27,28,29,30],"Mild Dementia","Mild Cognitive Impairment","SCD","Alzheimer Disease","Lewy Body Disease","Frontotemporal Degeneration","Vascular Dementia",[32],"Primary care, early diagnosis, blood, biomarkers, cognitive testing","RECRUITING","2026-04-01",{"date":36,"type":37},"2026-04-06","ACTUAL",{"date":39,"type":37},"2020-01-01",{"date":41,"type":20},"2028-12-31",{"name":43,"class":44},"Skane University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":45},"100525490","the-swedish-biofinder---memory-clinic-study-100525490","NCT06122415","The Swedish BioFINDER - Memory Clinic Study","Validate","Inclusion Criteria:\n\n1. Under investigation for cognitive symptoms at the Memory clinic.\n2. Cerebrospinal fluid and blood sampling is planned to be done as part of clinical practice even if the patient is not taking part of this study.\n\nExclusion Criteria:\n\n1. Not undergoing CSF or blood sampling as part of clinical practice.\n2. Not undergoing cognitive testing as part of clinical practice.",{"count":19,"type":20},"The diagnosis of diseases causing memory difficulties or dementia is often challenging. Without the use of advanced methods such as cerebrospinal fluid tests, approximately 25-30% do not receive a correct diagnosis today. However, the investigators have recently developed new blood biomarkers with high diagnostic accuracy, and the investigators now want to investigate whether they can eventually replace cerebrospinal fluid tests. This is because blood tests are much more cost-effective and significantly easier for patients compared to cerebrospinal fluid tests.\n\nIn this study, 1200 patients undergoing clinical evaluations at the Memory Clinic, Skåne University Hospital in Malmö, are included for blood and cerebrospinal fluid sample collection. The blood samples are sent for analysis using the new blood biomarkers. Subsequently, the results are compared with those from the clinical analysis of cerebrospinal fluid to determine how well they perform in routine clinical practice as an alternative to cerebrospinal fluid tests and whether the blood test improves patient care. This comparison is carried out by the attending physician in three steps:\n\n1. Assessment without access to the results of either the blood test or cerebrospinal fluid test.\n2. Assessment with access to only the results of the blood test.\n3. Assessment with access to the results of both the blood test and cerebrospinal fluid test.\n\nAim 1) To prospectively validate plasma Alzheimer's disease (AD) biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in a specialist memory clinic.\n\nAim 2) Determine whether blood AD biomarkers improve patient management in specialist memory clinic settings.",[24,25,26,27,28,29,30],{"date":36,"type":37},{"date":58,"type":37},"2022-12-01",{"date":60,"type":20},"2026-12-31",{"name":43,"class":44},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100607454","efficacy-of-liberal-versus-restricted-iv-fluid-approach-in-the-management-of-sickle-cell-vaso-occlusive-crisis-100607454","NCT07188766","Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis","Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive Versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)","FLASC","Inclusion Criteria:\n\n1. Patients \\>18 years old with a confirmed diagnosis of SCD.\n2. Presenting with a VOC.\n3. NPRS \\>5\n4. Willingness to participate and provide informed consent.\n\nExclusion Criteria:\n\n1. Patient requiring specialized IVF management as per the treating physician discretion.\n2. Patients with congestive heart failure, and \u002For acute or chronic symptomatic systolic heart failure\n3. Patients with ESRD on chronic dialysis\n4. Patients with signs of shock (low SBP \\\u003C100 or MAP \\\u003C 65) and signs of hypo perfusion\n5. Known or suspected pregnancy\n6. Previously enrolled in this trial within the last 30 days\n7. Enrolled in another trial study that interfered with fluid management\n8. Unable to obtain IV access.","18 Years","60 Years",{"count":73,"type":20},394,"INTERVENTIONAL",[76],"NA","Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC.\n\nThis multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles.\n\nWe hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.",[26,79],"Vaso Occlussive Crisis",[81,82,83,84],"sickle cell disease","sickle cell crisis","intravenous fluid","emergency department","2026-03-16",{"date":87,"type":37},"2026-03-18",{"date":89,"type":37},"2025-10-05",{"date":91,"type":20},"2028-10",{"name":93,"class":44},"Imam Abdulrahman Bin Faisal University",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":45},"100593698","neonatal-screening-for-haemoglobinopathies-emocamp-100593698","NCT07009821","Neonatal Screening for Haemoglobinopathies EmoCamp","SCREENING EmoCamp_ Analysis of Major Haemoglobinopathies Among Newborns in the Campania Region","EmoCamp","Inclusion Criteria:\n\n* newborns at higher risk of disease.\n\nExclusion Criteria:\n\n\\-",true,{"count":105,"type":20},1000,"Hereditary haemoglobin defects defined under the term haemoglobinopathies represent the most frequent congenital diseases worldwide.\n\nThe proposed observational study is aimed at determining the prevalence of haemoglobinopathies in newborns in the Campania Region. The neonatal screening test will be performed at the birth centers in Campania Region, before the newborn's discharge, at the same time as the sampling for neonatal screening required by law.\n\nThe main objective of this study is to evaluate the feasibility and impact of the screening programme performed at the birth centers on the earliness of diagnosis and the annual rate of sickle cell anaemia diagnosis in children. The secondary objective is to evaluate the benefits of early diagnosis of SCD in children as measured by two endpoints:\n\n* Improved disease management and early initiation of conventional therapy with reduction of complications, potentially fatal;\n* Difference between costs related to the neonatal screening programme and estimated costs related to conventional screening and treatment resulting from complications that may arise with late diagnosis.",[26],[26,109],"neonatal screening","NOT_YET_RECRUITING","2025-06-06",{"date":113,"type":37},"2025-06-08",{"date":115,"type":20},"2025-06",{"date":117,"type":20},"2027-09",{"name":119,"class":44},"Maddalena Casale",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":103,"sex":16,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":74,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":45},"100573486","identification-of-neuroinflammation-and-neuroimaging-biomarkers-through-data-driven-artificial-intelligence-techniques-for-unraveling-the-heterogeneity-of-aged-subjects-at-risk-of-dementia-and-to-better-inform-prevention-strategies-100573486","NCT06746909","Identification of Neuroinflammation and Neuroimaging Biomarkers Through Data Driven Artificial Intelligence Techniques for Unraveling the Heterogeneity of Aged Subjects at Risk of Dementia and to Better Inform Prevention Strategies","Inclusion Criteria:\n\n* age between 65 and 89 years; 5 years of schooling;\n* diagnosis of Mild Cognitive Impairment (Croisile et al., 2011) or\n* diagnosis of Subjective Cognitive Decline (Jessen et al., 2014).\n\nExclusion Criteria:\n\n* neurological pathologies; dementia;\n* psychiatric disorders;\n* pathologies or orthopedic problems limiting participation to the aerobic physical training program and to the MR imaging.","65 Years","89 Years",{"count":129,"type":20},115,[76],"SCD and MCI are very heterogeneous conditions, which can be prodromal to different types of dementia. The application of data driven clustering methods on neuroimaging and inflammatory data aims at identifying the features characterizing subgroups of subjects at high risk of developing overt dementia. This approach promises to develop tailored early interventions for subjects with profiles of cognitive decline correlating with high risk of progression. To this end in this project, we propose to examine in these subjects both brain structure and cerebral blood flow (CBF) through MR T1-weighted and pCASL (pseudo-continuous arterial spin labeling) imaging and the neuroinflammatory status. The latter will be done by measuring the populations of innate and adaptive immune cells, the chemokines that are required to attract these cells to their potential sites of action in the CNS, and the cytokines by means they exert their function. The analyses performed in aged subjects with MCI and in SCD, will allow identifying common mechanisms predisposing to an increased susceptibility to progression to overt cognitive decline.",[133,26,134],"MCI","Healthy","2024-12-20",{"date":137,"type":37},"2024-12-24",{"date":139,"type":37},"2022-02-01",{"date":141,"type":20},"2026-06-30",{"name":143,"class":44},"IRCCS Fondazione Stella Maris",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":21,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":45},"100562340","the-relationship-of-platelet-counts-with-sickle-cell-anemia-in-the-eastern-region-of-saudi-arabia-100562340","NCT06601894","The Relationship of Platelet Counts With Sickle Cell Anemia in the Eastern Region of Saudi Arabia","Inclusion criteria: All the diagnosed patients of sickle cell disease regardless of age and gender.\n\nExclusion criteria: Patients without having sickle cell disease regardless of age and gender.","1 Year",{"count":152,"type":20},650,"1 Month","This study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the Kingdom of Saudi Arabia.",[156,26],"Sickle Cell Anaemia","2024-10-03",{"date":159,"type":37},"2024-10-04",{"date":161,"type":20},"2024-12-01",{"date":163,"type":20},"2025-03-30",{"name":165,"class":44},"Majmaah University",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":103,"sex":16,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":176,"studyType":21,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":45},"100541897","the-effects-of-social-isolation-and-social-interaction-on-the-risk-of-dementia-progression-and-brain-function-in-scd-subjective-cognitive-decline-scd-100541897","NCT06335836","The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)","Inclusion Criteria:\n\n* SCD\n\n  1. Self-perceived continuous cognitive decline compared with the previous normal state, and is not related to acute events;\n  2. After adjustment for age, gender, and years of education, the standard cognitive test is normal, or the diagnostic criteria for MCI are not met;\n  3. Selected candidates can sign the informed consent form themselves.\n\nExclusion Criteria:\n\n* (a) Aged under 45 years or older than 85 years; (b) Vascular dementia or other central nervous system diseases; (c) Hachinski Ischemic Scale score \\> 4 points; (d); Unable to complete neuropsychological tests (e.g., blindness, deafness, severe language impairment); (e) Drug abuse or alcohol dependency within the last 6 months; (f) Current participation in other cognition studies; (g) Severe diabetes mellitus, or severe cardiovascular disease, cerebrovascular disease, liver diseases, kidney diseases, psychiatric disorders; (h) Contraindications to imaging techniques: claustrophobia, metallic implants (e.g., intracranial metal clips), electronic devices (e.g., cardiac pacemakers)","45 Years","85 Years",{"count":175,"type":20},209,"5 Years","The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD\n\n1. To explore the association between social isolation and lonely SCD populations and the occurrence and progression of MCI and AD through cross-sectional studies, cohort studies and randomized controlled trials of SCD;\n2. To clarify the correlation between different carrier states, resting brain function connectivity characteristics, and dual-task walking ability of APOEε4 allele and the progression of SCD to MCI and AD during the cognitive progress of people with SCD affected by social isolation;\n3. Establish a predictive model of cognitive decline from SCD to MCI and AD, and apply it to the SCD population to carry out individualized interventions;\n4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients.",[179,26,180,133,25,181,27],"Social Isolation","Subjective Cognitive Decline","AD","2024-03-21",{"date":184,"type":37},"2024-03-28",{"date":186,"type":37},"2024-03-01",{"date":188,"type":20},"2028-12-30",{"name":190,"class":44},"The First Affiliated Hospital with Nanjing Medical University"]